Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 1 to 25 of 1146 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
1085 increased wounding (MP:0013027) Nose (FMA:46472) 2312: Increased, nasal lesions
581 abnormal wound healing (GO:0042060) 1130: Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
97 abnormal Wnt signaling pathway (GO:0016055) Wnt signalosome (GO:1990909) 310: Alteration, Wnt pathway
725 increased Wnt protein secretion (GO:0061355) protein-serine O-palmitoleoyltransferase porcupine (PR:000030936) 1754: Increase, porcupine-induced Wnt secretion and Wnt signaling activation
597 decreased wellness/fitness trait (VT:1000152) 1135: Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction
31 decreased weight loss (MP:0001263) None
985 disrupted voltage-gated sodium channel activity (GO:0005248) 1353: Binding to voltage-gated sodium channel
591 abnormal vitamin K metabolic process (GO:0042373) vitamin K (CHEBI:28384) 1134: Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone
810 functional change vision trait (VT:0002090) eye (UBERON:0000970) 1643: Altered, Visual function
952 occurrence virus maturation (GO:0019075) 2192: Influenza A Virus production increased
954 occurrence virus induced gene silencing (GO:0009616) 2180: Immune mechanisms antagonized by viral proteins
763 increased viral translation (GO:0019081) ssRNA viral genome (GO:0019024) 1847: Increased SARS-CoV-2 production
756 increased viral RNA genome replication (GO:0039694) viral RNA-directed RNA polymerase complex (GO:0031381) 1847: Increased SARS-CoV-2 production
755 increased viral RNA genome replication (GO:0039694) None
761 increased viral RNA genome packaging (GO:0019074) viral assembly compartment (GO:0072516) 1847: Increased SARS-CoV-2 production
760 increased viral RNA genome packaging (GO:0019074) None
824 increased viral release from host cell (GO:0019076) 1939: Viral infection and host-to-host transmission, proliferated
951 occurrence viral mRNA export from host cell nucleus (GO:0046784) 2192: Influenza A Virus production increased
909 occurrence viral entry into host cell (GO:0046718) viral protein (PR:000036197) 1738: SARS-CoV-2 cell entry
908 occurrence viral entry into host cell (GO:0046718) viral genome (GO:0019015) 1738: SARS-CoV-2 cell entry
956 occurrence viral budding from plasma membrane (GO:0046761) 2193: Influenza A Virus (IAV) budding
964 decreased viable offspring quantity (VT:1000181) 2147: Decreased, Viable Offspring
945 occurrence vesicle targeting, plasma membrane to endosome (GO:0048201) None
759 increased Venous thrombosis (HP:0004936) platelet (CL:0000233) 1846: Thrombosis and Disseminated Intravascular Coagulation
490 abnormal vasodilation (GO:0042311) blood vessel (UBERON:0001981) 937: KE7 : Impaired, Vasodilation